January 11th 2023
New research identifies potential new TED biomarkers based on the disease activity or inactivity.
November 24th 2022
November 21st 2022
Phase 2 data finds OCS-01 improves macular thickness, VA in DME patientsSeptember 8th 2022
OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone that has the potential to be the first topical eye drop and non-invasive treatment for DME.
Risk of VA loss link found between DME eyes initially treated and observedApril 25th 2022
Investigators report a correlation between the risk of 5-letter visual acuity (VA) loss at 24 months for eyes with clinically significant diabetic macular edema (CSDME) and good VA initially treated and eyes that were initially observed in routine clinical practice.